Alumis Inc. (NASDAQ:ALMS) Sees Large Increase in Short Interest

Posted by George Bondi on Oct 17th, 2026

Alumis Inc. (NASDAQ:ALMS – Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 10,295,705 shares, an increase of 63.4% from the September 15th total of 6,299,106 shares. Approximately 12.0% of the shares of the company are short sold. Based on an average daily trading volume, of 2,869,547 shares, the short-interest ratio is currently 3.6 days.

Alumis Stock Performance

Shares of Alumis stock traded down $0.19 during midday trading on Friday, hitting $6.12. The company had a trading volume of 2,496,319 shares, compared to its average volume of 2,452,272. The stock has a market capitalization of $792.11 million, a P/E ratio of -1.59 and a beta of -0.38. The company has a 50 day moving average of $13.24 and a 200 day moving average of $20.60. Alumis has a 52-week low of $4.37 and a 52-week high of $31.35.

Alumis (NASDAQ:ALMS – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.34). The company had revenue of $1.66 million for the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative net margin of 5,933.46% and a negative return on equity of 93.15%. Equities research analysts forecast that Alumis will post -2.95 EPS for the current year.

Insiders Place Their Bets

In other Alumis news, Director Srinivas Akkaraju acquired 546,581 shares of Alumis stock in a transaction that occurred on Tuesday, September 8th. The stock was acquired at an average cost of $10.63 per share, for a total transaction of $5,810,156.03. Following the purchase, the director owned 4,937,026 shares of the company’s stock, valued at approximately $52,480,586.38. This represents a 12.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $67,823.64. Following the completion of the transaction, the insider owned 48,533 shares of the company’s stock, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 111,084 shares of company stock worth $1,408,493 in the last three months. Insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ALMS. BlackRock Inc. bought a new stake in Alumis in the 2nd quarter worth about $231,259,000. venBio Partners LLC purchased a new position in Alumis in the 2nd quarter worth about $127,429,401. Cormorant Asset Management LP lifted its stake in Alumis by 69.3% during the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after acquiring an additional 1,488,200 shares during the period. Octagon Capital Advisors LP lifted its stake in Alumis by 11.9% during the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock valued at $62,360,000 after acquiring an additional 300,000 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in shares of Alumis during the 2nd quarter valued at about $66,238,000.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ALMS. Wells Fargo & Company reduced their target price on Alumis from $51.00 to $25.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 2nd. Citigroup reiterated an “overweight” rating on shares of Alumis in a report on Tuesday, September 1st. Morgan Stanley dropped their price objective on Alumis from $39.00 to $29.00 and set an “overweight” rating for the company in a report on Wednesday, September 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Friday, October 2nd. Finally, Guggenheim lowered Alumis from a “buy” rating to a “neutral” rating in a research report on Thursday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Alumis presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.27.

Read Our Latest Research Report on ALMS

Alumis Company Profile

(Get Free Report)

Alumis, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases. The company’s research centers on selective allosteric inhibitors of tyrosine kinase 2 (TYK2), a protein involved in signaling pathways that regulate inflammation and immune responses.

Alumis’ lead product candidate is ESK-001, an oral, highly selective TYK2 inhibitor being evaluated in inflammatory and autoimmune conditions, including plaque psoriasis, psoriatic arthritis and systemic lupus erythematosus.